Psychiatry and Neurology, Neurology · New Haven, CT
NPI
1780632968
Since 2006
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
3
Medicare group memberships
Hospitals
3
Hospital affiliations
136 Sherman Ave, Suite 505
New Haven, CT, 06511
Phone (203) 562-8071
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.2M
34,699 services
Medicare patients, 2024
588
Average age 74
Drug cost, 2024
$2.5M
7,631 prescriptions
Company payments, 2025
$105K
From 50 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mayer J Hasbani was code 99213 (office e&m - established), 556 times for 353 patients. In total Mayer J Hasbani billed 34,699 services in 45 codes, and Medicare paid $1.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-08-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 556 | 353 | $70.59 | $39K |
| 99214 Office E&M - Established | Office | 212 | 155 | $102.46 | $22K |
| 95886 Electrical Nerve Conductivity | Office | 151 | 85 | $82.44 | $12K |
| 99204 Office E&M - New | Office | 124 | 123 | $126.93 | $16K |
| 99203 Office E&M - New | Office | 123 | 123 | $89.47 | $11K |
| 96372 Injection Administration | Office | 48 | 13 | $11.38 | $546 |
| 95911 Electrical Nerve Conductivity | Office | 29 | 29 | $178.55 | $5,178 |
| 64615 Musculoskeletal | Office | 24 | 12 | $104.18 | $2,500 |
| 95909 Electrical Nerve Conductivity | Office | 23 | 22 | $111.84 | $2,572 |
| 95908 Electrical Nerve Conductivity | Office | 21 | 21 | $88.65 | $1,862 |
| 62270 Musculoskeletal | Office | 12 | 12 | $127.88 | $1,535 |
| 95910 Electrical Nerve Conductivity | Office | 12 | 12 | $140.78 | $1,689 |
By year: 2022 $589K for 6,454 services; 2023 $506K for 13,374 services; 2024 $1.2M for 34,699 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mayer J Hasbani prescribed most often to Medicare patients was Gabapentin, with 986 prescriptions and refills. In total Mayer J Hasbani wrote 7,631 Medicare prescriptions that cost $2.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Gabapentin Generic | 986 | 1,353 | 201 | $16K |
| Topiramate Generic | 553 | 984 | 136 | $5,526 |
| Nortriptyline Hcl Generic | 474 | 776 | 130 | $9,206 |
| Donepezil Hcl Generic | 380 | 653 | 77 | $2,499 |
| Duloxetine Hcl Generic | 378 | 629 | 85 | $5,533 |
| Carbidopa-Levodopa Carbidopa/Levodopa | 286 | 580 | 65 | $6,836 |
| Pregabalin Generic | 268 | 310 | 58 | $9,879 |
| Clonazepam Generic | 255 | 322 | 42 | $1,945 |
| Levetiracetam Generic | 252 | 490 | 54 | $6,524 |
| Amantadine Amantadine Hcl | 204 | 332 | 40 | $8,980 |
| Rasagiline Mesylate Generic | 198 | 424 | 44 | $29K |
| Sumatriptan Succinate Generic | 123 | 135 | 23 | $5,669 |
| Sertraline Hcl Generic | 110 | 211 | 34 | $693 |
| Oxcarbazepine Generic | 102 | 160 | 20 | $3,542 |
| Lamotrigine Generic | 100 | 172 | 20 | $2,371 |
Brand drugs: 804 claims; generic drugs: 6,782 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mayer J Hasbani $105K ($105K in general payments such as food, travel and fees) from 50 companies. The largest payer was Amgen Inc. with $38K.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 45 | $38K |
| Otsuka America Pharmaceutical, Inc. 4578.T | 34 | $30K |
| Teva Pharmaceuticals USA, Inc. TEVA | 24 | $9,267 |
| Genzyme Corporation SNY | 10 | $6,666 |
| Genentech USA, Inc. ROG.SW | 17 | $4,699 |
| Abbvie Inc. ABBV | 41 | $4,501 |
| Eisai Inc. 4523.T | 8 | $4,417 |
| EMD Serono, Inc. MRK.DE | 22 | $936 |
| Lundbeck LLC | 32 | $657 |
| Amneal Pharmaceuticals LLC AMRX | 21 | $563 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.